This image depicts the structure of the BAX protein (purple). The activator compound BTSA1 (orange) has bound to the active site of BAX (green), changing the shape of the BAX molecule at several points (shown in yellow, magenta and cyan). BAX, once in its final activated form, can home in on mitochondria and puncture their outer membranes, triggering apoptosis (cell death).
Scientists atĀ Albert Einstein College of MedicineĀ have discovered the first compound that directly makes cancer cells commit suicide while sparing healthy cells. The new treatment approach, described in todayās issue ofĀ Cancer Cell, was directed against acute myeloid leukemia (AML) cells but may also have potential for attacking other types of cancers.
“Weāre hopeful that the targeted compounds weāre developing will prove more effective than current anti-cancer therapies by directly causing cancer cells to self-destruct,” saysĀ Evripidis Gavathiotis, Ph.D., associate professor ofĀ biochemistryĀ and ofĀ medicineĀ and senior author of the study. “Ideally, our compounds would be combined with other treatments to kill cancer cells faster and more efficientlyāand with fewer adverse effects, which are an all-too-common problem with standard chemotherapies.”
AML accounts for nearly one-third of all new leukemia cases and kills more than 10,000 Americans each year. The survival rate for patients has remained at about 30 percent for several decades, so better treatments are urgently needed.
The newly discovered compound combats cancer by triggering apoptosisāan important process that rids the body of unwanted or malfunctioning cells. Apoptosis trims excess tissue during embryonic development, for example, and some chemotherapy drugs indirectly induce apoptosis by damaging DNA in cancer cells.
Apoptosis occurs when BAXāthe āexecutioner proteinā in cellsāis activated by āpro-apoptoticā proteins in the cell. Once activated, BAX molecules home in on and punch lethal holes in mitochondria, the parts of cells that produce energy. But all too often, cancer cells manage to prevent BAX from killing them. They ensure their survival by producing copious amounts of āanti-apoptoticā proteins that suppress BAX and the proteins that activate it.
“Our novel compound revives suppressed BAX molecules in cancer cells by binding with high affinity to BAXās activation site,” says Dr. Gavathiotis. “BAX can then swing into action, killing cancer cells while leaving healthy cells unscathed.”
Dr. Gavathiotis was the lead author of aĀ 2008 paper inĀ NatureĀ that first described the structure and shape of BAXās activation site. He has since looked for small molecules that can activate BAX strongly enough to overcome cancer cellsā resistance to apoptosis. His team initially used computers to screen more than one million compounds to reveal those with BAX-binding potential. The most promising 500 compoundsāmany of them newly synthesized by Dr. Gavathiotisā teamāwere then evaluated in the laboratory.
“A compound dubbed BTSA1 (short for BAX Trigger Site Activator 1) proved to be the most potent BAX activator, causing rapid and extensive apoptosis when added to several different human AML cell lines,ā says lead author Denis Reyna, M.S., a doctoral student in Dr. Gavathiotisā lab. The researchers next tested BTSA1 in blood samples from patients with high-risk AML. Strikingly, BTSA1 induced apoptosis in the patientsā AML cells but did not affect patientsā healthy blood-forming stem cells.
Finally, the researchers generated animal models of AML by grafting human AML cells into mice. BTSA1 was given to half the AML mice while the other half served as controls. On average, the BTSA1-treated mice survived significantly longer (55 days) than the control mice (40 days), with 43 percent of BTSA1-treated AML mice alive after 60 days and showing no signs of AML.
Importantly, the mice treated with BTSA1 showed no evidence of toxicity. āBTSA1 activates BAX and causes apoptosis in AML cells while sparing healthy cells and tissuesāprobably because the cancer cells are primed for apoptosis,ā says Dr. Gavathiotis. He notes that his study found that AML cells from patients contained significantly higher BAX levels compared with normal blood cells from healthy people. “With more BAX available in AML cells,” he explained, “even low BTSA1 doses will trigger enough BAX activation to cause apoptotic death, while sparing healthy cells that contain low levels of BAX or none at all.”
Plans call for Dr. Gavathiotis and his team to see whether BTSA1 will show similar effectiveness when tested on animal models of other types of cancer.
Learn more:Ā Novel Treatment Causes Cancer to Self-Destruct Without Affecting Healthy Cells
The Latest on:Ā Cancer cells commit suicide
- Making immunotherapy more effective against small cell lung canceron August 3, 2022 at 10:00 am
Fred Hutchinson Cancer Center lung cancer scientists open a human trial after preclinical work shows that making small cell lung cancer more visible to immune cells can make the tumors more responsive ...
- Telix APAC Report: Regulatory Progress for Prostate and Kidney Cancer Imagingon August 1, 2022 at 5:11 pm
2 In China, 115,000 men are diagnosed with prostate cancer each year, increasing by approx. 6% each year and 73,000 people are diagnosed with renal cell carcinoma each year. Illuccix (TLX591-CDx ...
- Scientists Discover a Massacre: āAssassinā Cells Murder Innocent Cellson July 29, 2022 at 4:44 pm
University of Haifa research has identified killer cells. A process that involves the "murder" of living, newly-generated cells has been discovered for the first time in recent research conducted at ...
- Tips for Black male self care -beating the odds of premature death in Americaon July 28, 2022 at 7:38 pm
A.Z. Matthews learned that he had stage 3 cancer. Then he committed suicide. He was 29 ... āWe have to really start making the health of our cells a priority,ā maintains Adams.
- Waterloo Skin Cancer Practice Is First in Iowa to Offer Non-Surgical Technology For Treating Common Skin Cancerson July 27, 2022 at 6:28 am
BURR RIDGE, Ill., July 27, 2022 /PRNewswire/ -- SkinCure Oncology, the world leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiotherapy (Image-Guided SRT ...
- Engineering Discovery: the Story of SKIon July 17, 2022 at 10:34 pm
Cancer geneticist Kenneth Offit ... DNA damage triggers p53 to induce the cell to commit suicide. SKI development biologist and Howard Hughes Medical Institute Investigator Jennifer Zallen discovers ...
- Researchers discover DNA copy number alterations lead to changes in RNA circuits that impact melanoma metastasison July 14, 2022 at 1:54 pm
Most cancer research and available anticancer drugs ... NUCKS1andZC3H11A promote cell growth, migration and invasion in melanoma cell lines, and stimulated metastasis growth in mouse models ...
- Cancer Med Might Be Powerful Treatment for MSon July 14, 2022 at 7:24 am
Over time, the disease steadily worsens. Immune system cells called B-cells seem to play a key role in MS. That understanding led some doctors to start prescribing rituximab to MS patients ...
- Abortion Bans Could Put Lives of Cancer Patients in Jeopardyon July 12, 2022 at 9:15 am
"Chemotherapy for the most part impacts cell division, right? I mean, that's one of the main ways it kills cancer cells, because they just can't go on and divide and replicate and grow and spread.
- āOur brother shot our father dead. It was a heroic actāon July 7, 2022 at 10:37 pm
Sitting in his prison cell ... committed. Stratton had shot his own father, Colin, in the head. Glenn was living with his dad in 2018 when Colin was diagnosed with an aggressive form of bowel ...
viaĀ Google News and Bing News